SECuRE update
Filed with ASX · · 6 pages · English
Summary by 6ix AI
The safety profile of the treatment appears favorable, with most adverse events being mild or moderate in severity. Overall, seven participants have achieved complete response or undetectable disease, indicating considerable anti-tumor activity of the treatment in advanced prostate cancer patients.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/secure-update
Clarity Pharmaceuticals Ltd. on 6ix
In the deck
Earlier from Clarity Pharmaceuticals
- Data on SAR-bisPSMA to be presented at EANM
- Clarity receives $9.8 million R&D tax incentive refund
- Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma
- Clarity signs a Commercial Manufacturing Agreement
- Co-PSMA data published in the European Urology journal
Later from Clarity Pharmaceuticals
- Clarity Pharmaceuticals Announces SECuRE Trial Update on 8 GBq 67Cu-SAR-bisPSMA dose level with two additional complete responses
- Bioshares Biotech Summit Presentation
- Ph III CLARIFY trial target number of participants achieved
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals